Transient Osteoporosis of Pregnancy: A Possible Peptide Mediator

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00541645
Recruitment Status : Suspended
First Posted : October 10, 2007
Last Update Posted : March 18, 2008
Information provided by:
Hadassah Medical Organization

Brief Summary:

Transient osteoporosis of pregnancy (TOoP) is uncommonly encountered in orthopedic and obstetric practice, with most reports consisting of single cases.

This rare condition consists of significant osteoporosis affecting the hips and spine, causing significant morbidity, and putting young female patients at risk for vertebral and femoral neck fractures.

The pathogenesis of transient osteoporosis of pregnancy is unknown, with various theories as to its etiology.

Recently, a number of reports have described elevated levels of PTHrP in patients with transient osteoporosis in pregnancy and of the postpartum period Our goal in this study is to assess the role of PTHrP in transient osteoporosis of pregnancy

Condition or disease
Transient Osteperosis

Study Type : Observational
Time Perspective: Prospective

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • Signed Informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00541645

Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Efrain Liebner, MD Hadassah Medical Organization
Study Chair: Meir Liebergall, M.D Hadassah Medical Organization
Study Director: Tzvi Bar-Shavit, Ph.D The Hebrew University Identifier: NCT00541645     History of Changes
Other Study ID Numbers: Lib001-HMO-CTIL
First Posted: October 10, 2007    Key Record Dates
Last Update Posted: March 18, 2008
Last Verified: March 2008